SHANGHAI – Hutchison Medipharma Ltd., of Shanghai, one of China's biotech pioneers with a deep pipeline of small-molecule oncology and autoimmune candidates, has started dosing Chinese patients with neuroendocrine tumors (NETs) in a phase III trial of sulfatinib.